And studies show that many bone metabolism markers, including PTH, are associated with abnormal cortical bone density, TB density, abnormal bone microstructure, and fracture (32).Therefore, we included several bone metabolism markers recommended by the KDIGO (Kidney Disease: Improving Global Outcomes) guidelines for the initial evaluation CKD-MBD (i.e., intact PTH (iPTH), 25-hydroxyvitamin D (25-(OH)-VitD), corrected calcium (cCa), phosphate (P)) and areal bone mineral density (aBMD) measured by dual-energy X-ray absorptiometry (DXA) (33, 34). This evidence concerns the gene PTH and Marchiafava-Bignami disease.